Core Viewpoint - Tenet Healthcare (THC) has shown strong stock performance recently, with an 8.1% return over the past month, outperforming the S&P 500's 2.7% and the Zacks Medical - Hospital industry's 4.3% [1] Earnings Estimates - Tenet is expected to report earnings of $3.35 per share for the current quarter, reflecting a year-over-year increase of 14.3% [4] - The consensus earnings estimate for the current fiscal year is $15.54, indicating a year-over-year change of 30.8% [4] - For the next fiscal year, the consensus estimate is $15.96, showing a 2.7% increase from the previous year [5] Revenue Growth - The consensus sales estimate for the current quarter is $5.25 billion, representing a year-over-year change of 2.4% [10] - Estimated revenues for the current and next fiscal years are $21.15 billion and $22.14 billion, indicating changes of 2.4% and 4.6%, respectively [10] Recent Performance - In the last reported quarter, Tenet achieved revenues of $5.27 billion, a year-over-year increase of 3.3% [11] - The EPS for the same period was $4.02, compared to $2.31 a year ago, with a revenue surprise of 2.42% and an EPS surprise of 41.55% [11][12] Valuation - Tenet is graded A in the Zacks Value Style Score, indicating it is trading at a discount compared to its peers [16] - The evaluation of valuation multiples such as P/E, P/S, and P/CF suggests that Tenet's stock is fairly valued or undervalued relative to its historical values and peers [14][15] Conclusion - The Zacks Rank 2 for Tenet suggests potential outperformance in the near term, supported by strong earnings and revenue growth projections [17]

In the latest trading session, Tenet Healthcare (THC) closed at $191.78, marking a -2.35% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.3%. Elsewhere, the Dow saw a downswing of 0.48%, while the tech-heavy Nasdaq appreciated by 0.03%. Prior to today's trading, shares of the hospital operator had gained 15.2% outpaced the Medical sector's gain of 7.07% and the S&P 500's gain of 2.09%.The investment community will be closely monitoring the performance of Tenet He ...

Company Overview - Arcutis Biotherapeutics, Inc. (ARQT) is part of the Medical group, which consists of 979 companies and is currently ranked 8 in the Zacks Sector Rank [2] - The company is categorized under the Medical - Biomedical and Genetics industry, which includes 489 stocks and is ranked 147 in the Zacks Industry Rank [6] Performance Metrics - Year-to-date, Arcutis Biotherapeutics has gained approximately 6%, while the average return for Medical companies is -7.4%, indicating that ARQT is outperforming its peers [4] - The Zacks Consensus Estimate for ARQT's full-year earnings has increased by 25.7% over the past quarter, reflecting improved analyst sentiment and a stronger earnings outlook [4] Zacks Rank - Arcutis Biotherapeutics currently holds a Zacks Rank of 2 (Buy), which emphasizes its potential for improving earnings outlooks [3] - In comparison, another Medical stock, Tenet Healthcare (THC), has a Zacks Rank of 1 (Strong Buy) and has returned 31.2% year-to-date [5]

Core Insights - HCA Healthcare reported quarterly earnings of $6.84 per share, exceeding the Zacks Consensus Estimate of $6.19 per share, and up from $5.5 per share a year ago, representing an earnings surprise of +10.50% [1] - The company generated revenues of $18.61 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.68% and increasing from $17.49 billion year-over-year [2] - HCA shares have appreciated approximately 13.8% year-to-date, outperforming the S&P 500's gain of 8.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $5.52 on revenues of $18.45 billion, while for the current fiscal year, the estimate is $25.30 on revenues of $74.62 billion [7] - The estimate revisions trend for HCA was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Hospital industry, to which HCA belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Another competitor in the same industry, Universal Health Services, is expected to report quarterly earnings of $4.85 per share, reflecting a year-over-year increase of +12.5% [9]

Core Viewpoint - Tenet Healthcare (THC) has seen a 15.2% increase in shares over the past month, outperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings release [1] Estimates Movement - Estimates for Tenet Healthcare have trended upward in the past month, with a consensus estimate shift of 5.78% [2] VGM Scores - Tenet has a Growth Score of B, a Momentum Score of F, and a Value Score of A, placing it in the top 20% for the value investment strategy, resulting in an aggregate VGM Score of A [3] Outlook - The upward trend in estimates and the magnitude of revisions suggest a positive outlook for Tenet, reflected in a Zacks Rank 2 (Buy), indicating expectations for above-average returns in the coming months [4] Industry Performance - Tenet operates within the Zacks Medical - Hospital industry, where Universal Health Services (UHS) has gained 7.5% over the past month, reporting revenues of $4.1 billion with a year-over-year change of +6.7% and an EPS of $4.84 compared to $3.70 a year ago [5] Earnings Expectations for Industry Player - Universal Health Services is projected to post earnings of $4.89 per share for the current quarter, reflecting a year-over-year change of +13.5%, with a Zacks Consensus Estimate change of +1% over the last 30 days, resulting in a Zacks Rank 3 (Hold) [6]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Summary: Tenet Healthcare (THC) - Tenet Healthcare currently holds a Momentum Style Score of B, indicating a positive momentum outlook [2] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [3] - Over the past week, THC shares increased by 11.18%, outperforming the Zacks Medical - Hospital industry, which rose by 9.56% [5] - In a longer timeframe, THC shares have appreciated by 34.51% over the past month, compared to the industry's 13.64% [5] - Over the last quarter, THC shares rose by 23.59%, and over the past year, they gained 24.85%, while the S&P 500 saw movements of -2.56% and 11.12%, respectively [6] - The average 20-day trading volume for THC is 1,609,941 shares, indicating a bullish trend as the stock is rising with above-average volume [7] Earnings Outlook - In the past two months, 8 earnings estimates for THC have been revised upwards, while none have been revised downwards, increasing the consensus estimate from $12.12 to $12.69 [9] - For the next fiscal year, 4 estimates have moved up, while 3 have been revised down [9] Conclusion - Considering the positive momentum indicators and earnings outlook, Tenet Healthcare is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a strong candidate for near-term investment [11]

Group 1 - Acadia Healthcare Company, Inc. (ACHC) is experiencing significant attention from investors due to high implied volatility in its options market, particularly the Jun 20, 2025 $65 Call option [1] - Implied volatility indicates the market's expectation of future price movement, suggesting that investors anticipate a substantial price change or an upcoming event that could trigger a rally or sell-off [2] - Acadia Healthcare currently holds a Zacks Rank 3 (Hold) in the Medical - Hospital industry, which is in the top 35% of the Zacks Industry Rank, but analysts have not increased earnings estimates for the current quarter, with a consensus estimate dropping from 77 cents to 71 cents per share [3] Group 2 - The high implied volatility surrounding Acadia Healthcare may indicate a developing trading opportunity, as options traders often seek to sell premium on options with high implied volatility to capture decay [4]

Core Viewpoint - Acadia Healthcare reported quarterly earnings of $0.40 per share, exceeding the Zacks Consensus Estimate of $0.35 per share, but down from $0.84 per share a year ago [1][2] Financial Performance - The company achieved revenues of $770.51 million for the quarter ended March 2025, aligning with the Zacks Consensus Estimate and showing a slight increase from $768.05 million year-over-year [3] - Acadia Healthcare has surpassed consensus EPS estimates three times over the last four quarters, but has only topped revenue estimates once in the same period [2][3] Stock Performance - The stock has declined approximately 39.9% since the beginning of the year, contrasting with the S&P 500's decline of 3.8% [4] - The current Zacks Rank for Acadia Healthcare is 4 (Sell), indicating expectations of underperformance in the near future [7] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.77 on revenues of $852.98 million, and for the current fiscal year, it is $2.68 on revenues of $3.33 billion [8] - The trend of estimate revisions for Acadia Healthcare has been unfavorable leading up to the earnings release [7] Industry Context - The Medical - Hospital industry, to which Acadia Healthcare belongs, is currently ranked in the top 40% of over 250 Zacks industries, suggesting a favorable environment compared to the bottom 50% [9]

Core Insights - Tenet Healthcare (THC) reported quarterly earnings of $4.36 per share, exceeding the Zacks Consensus Estimate of $3.11 per share, and showing an increase from $3.22 per share a year ago, resulting in an earnings surprise of 40.19% [1] - The company generated revenues of $5.22 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.64%, although this represents a decline from year-ago revenues of $5.37 billion [2] - Tenet has consistently outperformed consensus EPS estimates over the last four quarters, achieving this four times [2] Earnings Outlook - The future performance of Tenet's stock will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.68 on revenues of $5.16 billion, and for the current fiscal year, it is $12.15 on revenues of $20.87 billion [7] Industry Context - The Medical - Hospital industry, to which Tenet belongs, is currently ranked in the top 6% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]

Core Insights - Universal Health Services (UHS) reported quarterly earnings of $4.84 per share, exceeding the Zacks Consensus Estimate of $4.36 per share, and up from $3.70 per share a year ago, representing an earnings surprise of 11.01% [1] - The company posted revenues of $4.1 billion for the quarter ended March 2025, which was 1.06% below the Zacks Consensus Estimate, but an increase from $3.84 billion year-over-year [2] - UHS has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates three times as well [2] Earnings Outlook - The sustainability of UHS's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $4.84 on revenues of $4.21 billion, and for the current fiscal year, it is $18.94 on revenues of $17.12 billion [7] Industry Context - The Medical - Hospital industry, to which UHS belongs, is currently ranked in the top 11% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]